NY-ESO-1 targeted TCR therapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for NY-ESO-1 targeted TCR therapy, covering 2022-05-31 to 2022-05-31. Get the full timeline:
Most recent: Clinical Trial Update: Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 [Phase 1, Phase 2]